Novel influenza A (H1N1) is a new flu virus of swine origin that was first detected in Mexico and the United States in March and April, 2009. The first novel H1N1 patient in the United States was confirmed by laboratory testing at CDC on April 15, 2009. The second patient was confirmed on April 17, 2009. It was quickly determined that the virus was spreading from person-to-person. On April 22, CDC activated its Emergency Operations Center to better coordinate the public health response. On April 26, 2009, the United States Government declared a public health emergency.
It’s thought that novel influenza A (H1N1) flu spreads in the same way that regular seasonal influenza viruses spread; mainly through the coughs and sneezes of people who are sick with the virus.
In response to cases of swine influenza A(H1N1), reported in Mexico and the United States of America, the Director-General convened a meeting of the Emergency Committee to assess the situation and advise her on appropriate responses.
The United States Government has reported seven confirmed human cases of Swine Influenza A/H1N1 in the USA (five in California and two in Texas) and nine suspect cases.
"Where there are many scientific works dealing solely with the flu virus, we have investigated how the host reacts to an infection," says Klaus Schughart, head of the Experimental Mouse Genetics research group.
Influenza A viruses (H1N1 subtype) that are resistant to the drug oseltamivir circulated widely in the U.S. during the 2007-2008 influenza season, with an even higher prevalence of drug resistance during the current 2008-2009 influenza season, according to a study to be published in the March 11 issue of JAMA, the Journal of the American Medical Association.
A mutation of the influenza A(H1N1) virus that is resistant to the drug oseltamivir may pose a serious health threat to hospitalized patients who have a weakened immune system, according to a study to be published in the March 11 issue of JAMA, the Journal of the American Medical Association, and being released early online because of its public health importance.
Scientists have identified a small family of lab-made proteins that neutralize a broad range of influenza A viruses, including the H5N1 avian virus, the 1918 pandemic influenza virus and seasonal H1N1 flu viruses.
Scientists have identified a small family of lab-made proteins that neutralize a broad range of influenza A viruses, including the H5N1 avian virus, the 1918 pandemic influenza virus and seasonal H1N1 flu viruses.
Researchers at the Dana-Farber Cancer Institute (Dana-Farber), Burnham Institute for Medical Research (Burnham) and the Centers for Disease Control and Prevention (CDC) have reported the identification of human monoclonal antibodies (mAb) that neutralize an unprecedented range of influenza A viruses, including avian influenza A (H5N1) virus, previous pandemic influenza viruses, and some seasonal influenza viruses.
GlaxoSmithKline (GSK) is prepared to respond to public health needs for Relenza (zanamivir) Inhalation Powder this flu season following a Health Alert Advisory issued by the Centers for Disease Control and Prevention (CDC).
Novavax, Inc. has announced favorable results from a Phase IIa human clinical trial of its seasonal influenza VLP (trivalent) vaccine candidate.
Giving people age 65 and older a dose four times larger than the standard flu vaccine boosts the amount of antibodies in their blood to levels considered protective against the flu, more so than the standard flu vaccine does. The findings from a study of nearly 4,000 people were presented Oct. 26 at a national meeting on infectious diseases.
A single vaccine could be used to protect chickens, cats and humans against deadly flu pandemics, according to an article published in the November issue of the Journal of General Virology. The vaccine protects birds and mammals against different flu strains and can even be given to birds while they are still in their eggs, allowing the mass vaccination of wild birds.
Scientists have uncovered a change in the H5N1 bird flu virus which makes it resistant to the anti-viral drug Tamiflu. The mutation in the N1 component was found in human cases of the disease and suggests that a single drug approach is likely to be ineffective in case of a bird flu pandemic in humans. The findings by a team at the Medical Research Council's National Institute for Medical Research are published in Nature.
The World Health Organisation (WHO) is warning Australians to prepare for a potentially deadly flu season.
The exchange of genetic material between two closely related strains of the influenza A virus may have caused the 1947 and 1951 human flu epidemics, according to biologists.
Reassortment of the influenza A virus occurs frequently throughout its evolutionary history, according to a new study published February 29 in the open-access journal PLoS Pathogens.
Preliminary surveillance into antiviral drug susceptibility against seasonal flu viruses currently circulating in Europe has revealed that some of the A (H1N1) viruses (13%) have shown resistance to the antiviral drug, oseltamivir.
The Health Protection Agency has confirmed that the rate at which influenza viruses are now circulating in England has reached the point which triggers the use of antiviral drugs.
NanoViricides, Inc. has said that in a confirmatory study, their nanoviricide drug candidates exhibited a consistent 20% to 30% survival in the test animals.
St. Jude scientists have found key features that distinguish influenza viruses found in birds from those that infect humans.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.